A group more than a dozen shoppers entered the store - thought to be a Tesco in Chelmsford, Essex - without face coverings in protest against the current national COVID restrictions.
A group more than a dozen shoppers entered the store - thought to be a Tesco in Chelmsford, Essex - without face coverings in protest against the current national COVID restrictions.
Comfy as a sock, sturdy as a shoe, shoppers love them so much, they wear them around the house.
"I do skincare but my skin doesn’t care."
Cindy A. Kitner, CPA, President and Chief Executive Officer of Jefferson Security Bank, was recently appointed to the FDIC’s Advisory Committee on Community Banking. The Advisory Committee, which meets several times per year, provides advice and recommendations to the FDIC on a broad range of community bank policy and regulatory matters. Kitner is one of 17 members on the Advisory Committee, which is represented by a cross-section of community bankers from around the country.
Boris Johnson confirms James Dyson texts will be published on Friday. PM says there was nothing ‘remotely dodgy’ about exchanges he had with billionaire about tax affairs
EU financial services firms prioritise London with increased demand for UK authorisation
The "Freight Transport by Road in South Africa 2021" report has been added to ResearchAndMarkets.com's offering.
Gymnast Simone Biles captured the attention of sports fans for her talent both on the mat and off, such as the backflip she performed on the pitcher's mound in Houston before throwing out the first pitch during the 2019 World Series. Now she's attracted the attention of Gap's (NYSE: GPS) Athleta brand, which announced today that it has signed the sports star to represent the athleisure apparel company under a long-term contract. It's a major blow to Nike (NYSE: NKE), as Biles was a brand ambassador for the sporting goods company, though she never figured prominently in any of its ads.
For well over a month now, the IRS has been busy issuing stimulus checks to eligible Americans. Since the $1.9 trillion American Rescue Plan was signed into law, the IRS has been furiously blasting out stimulus payments in batches. This week, the IRS issued a sixth batch of $1,400 checks to reach more recipients.
The Biden administration has taken the first step toward ending an emergency exception that allowed hospitals to ration and reuse N95 medical masks, the first line of defence between frontline workers and the deadly coronavirus. Thousands of medical providers have died in the COVID-19 pandemic, many exposed and infected while caring for patients without adequate protection. Critical shortages of masks, gowns, swabs, and other medical supplies prompted the Trump administration to issue guidelines for providers to ration, clean, and reuse disposable equipment. Thus, throughout the pandemic, once a week many doctors and nurses were issued an N95 mask, which is normally designed to be tossed after each patient. Now U.S. manufacturers say they have vast surpluses for sale, and hospitals say they have three to 12 month stockpiles. In response, the government says hospitals and healthcare providers should try to return to one mask per patient. “The U.S. Food and Drug Administration (FDA) is recommending health care personnel and facilities transition away from crisis capacity conservation strategies,” said the agency in a letter to healthcare personnel and facilities earlier this month. The letter is not an order: hospitals are still legally permitted to sterilize and reuse N95s. But in the coming weeks or months, the FDA will issue updated guidance and, eventually, require hospitals to revert to single-use, said Suzanne Schwartz, director of the FDA’s office of strategic partnerships and technology innovation. “The ability to decontaminate was purely a last resort, an extreme measure,” Schwartz said. “From the FDA’s perspective, there is a need for us to move back towards contingency and conventional strategies, which is, you use the respirator for the interaction, and then you dispose of it and get a new one. We are in unison, in sync, with both NIOSH and OSHA in that position.” The National Nurses Union, the largest professional association of registered nurses in the country, calls the new guidance “a tiny step in the right direction.” But the organization, representing 170,000 nurses, said the direction “ultimately fails” to protect nurses because it allows employers to use their discretion about what normal N95 supply is. “But we know the reality— there is ample N95 supply,” said the union in a statement urging the administration to update their standards and enforce them. ICU nurse Mike Hill, who works at a Northern California Sutter Hospital and is a member of the California Nurses Association, said he and his colleagues still don’t have unlimited access to N95 masks. “I think it’s ridiculous for Sutter to want to do extended use when the masks are inexpensive, like a dollar apiece. They should want to make sure to protect the nurses, we’re the frontline workers,” he said. “It puts the patients and us at risk for infection. They were never intended for extended use.” Hill’s colleague, Sutter nurse Janine Paiste-Ponder, 59, was among hundreds of medical caregivers who died after exposure to COVID-19 at the workplace in the past year. Following her July 2020 death, a California’s Division of Occupational Safety and Health investigation at Sutter Health’s Alta Bates Summit Medical Center led to $155,250 in fines for numerous Covid-related workplace safety violations. Prestige Ameritech CEO Mike Bowen, whose Fort Worth, Texas factory is the largest U.S.-manufacturer of N95 masks, said the devices were designed to be used only once, not reused from one patient to the next. He said he has millions of unsold masks, as do other U.S. manufacturers which invested and ramped up during the pandemic. “While nurses pleaded for clean masks, American N95 makers were filling their warehouses with N95s that hospitals weren’t buying. Starting today, America’s healthcare workers can and should demand clean, new N95 masks,” he said. “The N95 mask shortage is over,” he said. Congresswoman Anna Eshoo said the deadly shortages were “a national embarrassment and should never happen again.” “This is welcome news and demonstrates our progress toward crushing COVID-19,” said the California democrat. “We must make sure this type of shortage never happens again by reinvesting in a sustainable supply of high-quality, American-made PPE.” —— Contact the reporters on Twitter at https://twitter.com/JulietLinderman and https://twitter.com/mendozamartha —— Contact AP’s global investigative team at Investigative@ap.org. Martha Mendoza And Juliet Linderman, The Associated Press
The way you save now can help keep your taxes low in your later years.
If he isn't just a copy and paste of his mom…
U.S. investment fund Davidson Kempner and British investment firm Pioneer Point Partners will jointly invest up to 3.5 billion euros ($4.2 billion) by 2025 in a large-scale data centre in Portugal to tap demand from global tech firms. The two companies said in a joint statement on Friday the campus in the city of Sines, 150 km (93 miles) south of the capital Lisbon, will include five buildings with a useful capacity to supply up to 450 megawatts of cheap energy from renewable sources to the servers. Prime Minister Antonio Costa later hailed the project as "the largest foreign direct investment in Portugal in recent decades", expecting Sines to attract further foreign investment with a government plan to install a green hydrogen production hub there.
PEOPLE and EW bring the shimmer to your sofa on Hollywood's biggest night
‘So much has been taken from us’: former post office operators speak out. Victims of England’s biggest ever miscarriages of justice talk of shocking impact on whole families
Sheridan Wyoming, April 23, 2021 (GLOBE NEWSWIRE) -- Appliqate Inc. (OTC: APQT) announces the return to in-person events with the company’s event portfolio. ELEV8, a hybrid event platform for connecting executives, and investors of blockchain, distributed ledger technologies, and digital assets, will host a two-day summit on June 2nd and 3rd in Miami during Bitcoin Week 2021. Executives from Appliqate and ELEV8 will be attending Bitcoin2021 which is one of the largest industry gatherings for bitcoin and digital assets including high profile speakers such as Jack Dorsey, co-founder, CEO & chairman of Square, Michael Saylor, Chairman & CEO of MicroStrategy, Chamath Palihapitiya, Managing Partner of Social Capital, and Senator Cynthia Lumis, State of Wyoming. The ELEV8 Summit will address NFT’s, ALT Coins, blockchain adoption, cryptocurrencies, and the state of the institutional and retail market. Participants will attend a welcome reception on the evening of June 2nd followed by a full day of content and networking on June 3rd. In 2021 bitcoin and cryptocurrency reached all-time highs resulting in unprecedented investments from corporations, institutional investors, and new retail investors. The program will feature leading organizations that are bullish within the sector and see a future where bitcoin’s market cap continues to grow into the trillions. ELEV8 will be announcing the full speaker roster in the near future. For more information visit https://www.elev8con.com/elev8-miami-summit-2021/ Past participating organizations have included NASDAQ, TDAmeritrade, State Street, JP Morgan, BlockFi, Celsius Network, Chainalysis, Galaxy Digital, Gemini, Wisdom Tree, and many other global institutions. “Appliqate is thrilled to welcome back in-person events through our portfolio company ELEV8. This last year taught us that purely virtual events struggle to fulfill our needs. We need to connect our communities with face-to-face connections so that we can recover……..this is vital .” stated Una Taylor, Founder and CEO. About ELEV8 ELEV8’s vision is that emerging new technologies such as digital assets, cryptocurrencies, AI, and blockchain create a more interconnected economic global ecosystem, working to eliminate barriers to growth and creating increased value for stakeholders across all industries. We believe future technologies will serve as the foundation for new economic systems which are more efficient, open, and accessible. Our mission is to enable that progress with industry research, distribution of the most current news, and hosting industry events that convene executives at the forefront of shaping the future of emerging technology. Our platform is home to the world’s leading tech experts; we collaborate with industry stakeholders across vertical markets and openly share insight. ELEV8 is at the forefront of shaping the future. View ELEV8’s research & industry content here: https://www.elev8con.com/industry-content/ About Appliqate Inc: Appliqate Inc is a publicly traded technology development firm that provides businesses, executives and investors access to capital and innovative solutions by utilizing platforms and business models to disrupt industry sectors. With an emphasis on media, blockchain, live entertainment, and intellectual property, the company accelerates the growth of tech solutions in these markets. Appliqate’s management team represents a unique combination of technology development, operating, investing, financial and transactional expertise. Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the SEC including the Current Reports on Form 8-K and the Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. For more information contact: Contact: Una Taylor: Una@Appliqate.com Inquires: Investorrelations@appliqate.com www.appliqate.com
PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to Obtain Regulatory Approval in Europe$10MM Milestone Payment Earned by AnaptysBio Upon EC Approval; Additional $35MM and $165MM Milestones Due Upon Dostarlimab Regulatory and Commercial Milestones, RespectivelyAnaptysBio Due to Receive 8% to 25% Royalty on Global Net Sales of Dostarlimab SAN DIEGO, April 23, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the European Commission has granted conditional marketing authorization for JEMPERLI (dostarlimab) for use in women with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen. The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe. JEMPERLI was generated by AnaptysBio using its proprietary somatic hypermutation (SHM) antibody platform and subsequently developed by TESARO, Inc., now a part of GSK, under a collaboration agreement. Eight AnaptysBio-generated therapeutic antibodies have advanced into clinical development to date, and JEMPERLI is the first AnaptysBio-generated antibody to obtain regulatory approval. “We are delighted that JEMPERLI is the first AnaptysBio-generated antibody to be approved in Europe and look forward to meaningful potential future milestone and royalty revenue from our collaboration with GSK,” said Hamza Suria, president and chief executive officer of AnaptysBio. “These revenues will continue to support AnaptysBio’s primary value-creation strategy, which is focused on advancing wholly-owned first-in-class therapeutic antibodies through multiple upcoming clinical catalysts in 2021 and 2022.” JEMPERLI is indicated as a monotherapy for treatment of adult patients with recurrent or advanced dMMR/MSI-H endometrial cancer, who have progressed on, or are being dosed following, prior treatment with a platinum-containing regimen, and is the first indication approved by the European Commission for JEMPERLI. AnaptysBio has earned a $10.0 million milestone payment as a result of this approval. Earlier this month, AnaptysBio earned a $20.0 million milestone payment as a result of approval by the U.S. Food and Drug Administration for JEMPERLI in endometrial cancer. In 2020, AnaptysBio received milestone payments of $10.0 million and $5.0 million for the FDA’s and EMA’s acceptances of the BLA and Marketing Authorisation Application (MAA) filings for JEMPERLI, respectively. Earlier this year, FDA accepted a subsequent BLA filing for JEMPERLI for the treatment of adult patients with dMMR recurrent or advanced solid tumors who have progressed on or following prior treatment. AnaptysBio recently received a $10.0 million payment from GSK as a result of this milestone. Payments totaling an additional $35 million will be due to AnaptysBio upon the achievement of future regulatory milestones for JEMPERLI in the United States and Europe. Furthermore, $165 million in sales milestones are due to AnaptysBio upon achievement of certain annual JEMPERLI net sales revenues. Royalties due to AnaptysBio for dostarlimab range from 8% to 25% of global net sales, where AnaptysBio will receive 8% of annual global net sales below $1 billion, and 12-25% of net sales above $1 billion. JEMPERLI is also being developed by GSK for the treatment of other tumor types and treatment settings, including currently ongoing phase III trials in recurrent or primary advanced endometrial cancer in combination with chemotherapy standard of care (RUBY) and the phase III FIRST study of platinum-based therapy with dostarlimab and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV non-mucinous epithelial ovarian cancer. In addition, JEMPERLI is being evaluated as monotherapy and in combination therapy across multiple tumor types and other cancers, including platinum-resistant ovarian cancer, non-small cell lung cancer, multiple myeloma and melanoma. GSK continues to develop additional antibodies partnered with AnaptysBio, including cobolimab, an AnaptysBio-generated anti-TIM-3 antagonist antibody, and GSK4074386, an anti-LAG-3 antagonist antibody. Under the terms of the collaboration, AnaptysBio is due to receive development and regulatory milestone payments for each of the first two indications for each of these antibodies. AnaptysBio can potentially receive a total of $1.1 billion in aggregate milestone payments under this collaboration. In addition, AnaptysBio will receive royalties ranging from 4% to 8% on global net sales of cobolimab and GSK4074386 and 1% of GSK’s global net sales of ZEJULATM. Important Information for JEMPERLI in the EU IndicationJEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen. Immune-Mediated Adverse Reactions Immune-related adverse reactions, which may be severe or fatal, can occur in patients treated with antibodies blocking the programmed cell death protein-1 / programmed death-ligand 1 (PD-1/PD-L1) pathway, including JEMPERLI. While immune-related adverse reactions usually occur during treatment with PD-1/PD-L1 blocking antibodies, symptoms can also manifest after discontinuation of treatment. Immune-related adverse reactions may occur in any organ or tissue and may affect more than one body system simultaneously. Important immune-related adverse reactions listed in this section are not inclusive of all possible severe and fatal immune-related reactions. Early identification and management of immune-related adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Patients should be monitored for symptoms and signs of immune-related adverse reactions. Clinical chemistries, including liver tests and thyroid function tests, should be evaluated at baseline and periodically during treatment. For suspected immune-related adverse reactions, adequate evaluation including specialty consultation should be ensured. Based on the severity of the adverse reaction, treatment with JEMPERLI should be withheld or permanently discontinued and corticosteroids (1 to 2 mg/kg/day prednisone or equivalent) or other appropriate therapy administered. Upon improvement to Grade ≤1, corticosteroid taper should be initiated and continued for 1 month or longer. Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Hormone replacement therapy for endocrinopathies should be instituted as warranted. Treatment with JEMPERLI should be permanently discontinued for any Grade 3 immune-related adverse reaction that recurs and for any Grade 4 immune-related adverse reaction toxicity, except for endocrinopathies that are controlled with replacement hormones and unless otherwise specified in the Summary of Product Characteristics (SmPC). Immune-Related Pneumonitis Pneumonitis has been reported in patients receiving JEMPERLI. Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other causes excluded. Patients should be managed with JEMPERLI treatment modifications and corticosteroids. Immune-related pneumonitis occurred in 7 (1.4%) of 515 patients, including Grade 2 (1.2%) and Grade 3 (0.2%) pneumonitis. Pneumonitis led to discontinuation of JEMPERLI in 3 (0.6%) patients. Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in all 7 patients experiencing pneumonitis. Pneumonitis resolved in 6 (85.7%) patients. Immune-Related ColitisJEMPERLI can cause immune-related colitis. Patients should be monitored for signs and symptoms of colitis and managed with treatment modifications, anti-diarrhoeal agents and corticosteroids. Colitis occurred in 8 (1.6%) patients, including Grade 2 (1.0%) and Grade 3 (0.6%) colitis. Colitis did not lead to discontinuation of JEMPERLI in any patients. Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in 2 (28.6%) patients. Colitis resolved in 6 (75.0%) patients experiencing colitis. Immune-Related HepatitisJEMPERLI can cause immune-related hepatitis. Patients should be monitored for changes in liver function periodically as indicated, based on clinical evaluation and managed with JEMPERLI treatment modifications and corticosteroids. Hepatitis occurred in 1 (0.2%) patient, which was Grade 3. Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required. Hepatitis did not lead to discontinuation of JEMPERLI and resolved. Immune-Mediated Endocrinopathies Hypothyroidism occurred in 37 (7.2%) patients, all of which were Grade 2. Hypothyroidism did not lead to discontinuation of JEMPERLI and resolved in 13 (35.1%) patients. Hyperthyroidism occurred in 10 (1.9%) patients, including Grade 2 (1.7%) and Grade 3 (0.2%). Hyperthyroidism did not lead to discontinuation of JEMPERLI and resolved in 8 (80%) patients. Thyroiditis occurred in 2 (0.4%) patients; both were Grade 2. Neither event of thyroiditis resolved; there were no discontinuations of JEMPERLI due to thyroiditis. Adrenal insufficiency occurred in 7 (1.4%) patients, including Grade 2 (0.8%), and Grade 3 (0.6%). Adrenal insufficiency resulted in discontinuation of JEMPERLI in 1 (0.2%) patient and resolved in 2 (28.6%) patients. Immune-Mediated Nephritis Nephritis, including tubulointerstitial nephritis, occurred in 3 (0.6%) patients; all were Grade 2. Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in 2 (66.7%) patients experiencing nephritis. Nephritis led to discontinuation of JEMPERLI in 1 (0.2%) patient and resolved in 2 of 3 (66.7%) patients. Immune-Related RashImmune-related rash occurred in 17 (3.3%) patients, including Grade 3 in 6 (1.2%) patients receiving JEMPERLI. The median time to onset of rash was 41 days (range 2 days to 407 days). Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in 5 (29%) patients experiencing rash. Rash did not lead to discontinuation of JEMPERLI and resolved in 13 (76.5%) patients. Immune-Related ArthralgiaImmune-related arthralgia occurred in 21 (4.1%) patients. Grade 3 immune-related arthralgia was reported in 3 (0.6%) patients receiving JEMPERLI. The median time to onset of arthralgia was 87 days (range 1 day to 783 days). Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in 2 (9.5%) patients experiencing arthralgia. Arthralgia did not lead to discontinuation of JEMPERLI and resolved in 8 (38%) patients experiencing arthralgia. Other Immune-Related Adverse ReactionsGiven the mechanism of action of JEMPERLI other potential immune-related adverse reactions may occur, including potentially serious events [e.g. myositis, myocarditis, encephalitis, demyelinating neuropathy (including Guillain Barré syndrome), sarcoidosis]. Clinically significant immune-related adverse reactions reported in less than 1% of patients treated with JEMPERLI as monotherapy in clinical studies include autoimmune haemolytic anaemia, pancreatitis, iridocyclitis, uveitis and diabetic ketoacidosis. Patients should be monitored for signs and symptoms of immune-related adverse reactions and managed as described in the SmPC. Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors. Treatment with JEMPERLI may increase the risk of rejection in solid organ transplant recipients. The benefit of treatment with JEMPERLI versus the risk of possible organ rejection should be considered in these patients. Fatal and other serious complications can occur in patients who receive allogeneic haematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1–blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GvHD), acute GvHD, chronic GvHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1–blocking antibody prior to or after an allogeneic HSCT. Infusion-Related Reactions Infusion-related reactions including hypersensitivity occurred in 7 (1.4%) patients, including Grade 2 (1.2%) and Grade 3 (0.2%) infusion-related reactions. All patients recovered from the infusion-related reaction. ImmunogenicityAnti-drug antibodies (ADA) were tested in 315 patients who received JEMPERLI and the incidence of JEMPERLI treatment-emergent ADAs was 2.5%. Neutralising antibodies were detected in 1.3% of patients. In the patients who developed anti-JEMPERLI antibodies, there was no evidence of altered efficacy or safety of JEMPERLI. Elderly populationOf the 515 patients treated with JEMPERLI monotherapy, 50.7% were under 65 years, 37.9% were 65-75 years, and 11.5% were 75 years or older. No overall differences in safety were reported between elderly (≥ 65 years) and younger patients (< 65 years). Pregnancy, Lactation and FertilityJEMPERLI is not recommended during pregnancy and in women of childbearing potential not using contraception. JEMPERLI should not be used during breast-feeding and breast-feeding should be avoided for at least 4 months after the last dose of JEMPERLI. Fertility studies have not been conducted with JEMPERLI. COMMON ADVERSE REACTIONSJEMPERLI is most commonly associated with immune-related adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of JEMPERLI. In patients with advanced or recurrent solid tumours (N = 515), the most common adverse reactions (> 10%) were anaemia (25.6%), nausea (25.0%), diarrhoea (22.5%), vomiting (18.4%), arthralgia (13.8%), pruritus (11.5%), rash (11.1%), pyrexia (10.5%) and hypothyroidism (10.1%). JEMPERLI was permanently discontinued due to adverse reactions in 17 (3.3%) patients; most of them were immune-related events. Adverse reactions were serious in 8.7% of patients; most serious adverse reactions were immune-related adverse reactions. Refer to the JEMPERLI Prescribing Information for a full list of adverse events and the complete important safety information. About AnaptysBio AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The Company’s proprietary anti-inflammatory pipeline includes imsidolimab, its anti-IL-36R antibody, previously referred to as ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, EGFRi skin toxicity, ichthyosis, hidradenitis suppurativa and acne; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the milestones and royalty payments to be received under the GSK partnership and the timing of the release of data from our clinical trials. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Contact:Dennis MulroyAnaptysBio, Inc.firstname.lastname@example.org
Sports quiz of the week: Ronnie O’Sullivan, Ryan Mason and Hull KR. Who started quickly? Who is still going? Who held out?
CLEVELAND — The Browns exercised the fifth-year option on quarterback Baker Mayfield's rookie contract on Friday, an expected move after his strong 2020 season. The team did the same with top cornerback Denzel Ward's contract. Mayfield had 30 touchdown passes last season and led the Browns to their first playoff appearance in nearly 20 years. Cleveland won its first post-season game since 1994, beating the Pittsburgh Steelers in the wild-card round before losing to Kansas City. The team had until May 3 to exercise the option, which means Mayfield, who was the No. 1 overall draft pick in 2018, is under contract for 2021 and 2022 — and those deals are guaranteed. The Browns may soon discuss a long-term extension with Mayfield, who has shown major growth on and off the field during his three seasons with Cleveland, easing concerns last year about whether he was their long-term solution at QB. Ward was drafted three picks after the Browns selected Mayfield three years ago. The former Ohio State standout has developed into one of the NFL's better coverage cornerbacks. Ward, who made the Pro Bowl as a rookie, has seven interceptions in three seasons. ___ More AP NFL coverage: https://apnews.com/hub/NFL and https://twitter.com/AP_NFL Tom Withers, The Associated Press
The failure of the ESL does not represent a victory of fans over commerce, or of culture over capitalism. It is the very existence of fans that cements football’s commercial nature.
Applicant Tracking Systems Market In US 2021-2025. The analyst has been monitoring the applicant tracking systems market in the US and it is poised to grow by $ 138. 06 mn during 2021-2025, progressing at a CAGR of almost 7% during the forecast period.New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Applicant Tracking Systems Market in US 2021-2025" - https://www.reportlinker.com/p03793938/?utm_source=GNW Our report on applicant tracking systems market in the US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current us market scenario, latest trends and drivers, and the overall market environment. The market is driven by cost-effective and less time-consuming services and increasing enrollment of foreign students. In addition, cost-effective and less time-consuming service is anticipated to boost the growth of the market as well.The applicant tracking systems market in US analysis includes end-user segment and deployment segment.The applicant tracking systems market in the US is segmented as below:By End-User• Technology• Healthcare• Financial services• Retail• OthersBy Deployment• Cloud-based• On-premisesThis study identifies the growing emphasis on streamlining HR functions as one of the prime reasons driving the applicant tracking systems market in US growth during the next few years.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on applicant tracking systems market in the US covers the following areas:• Applicant tracking systems market in US sizing• Applicant tracking systems market in US forecast• Applicant tracking systems market in US industry analysisThis robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading applicant tracking systems market in US vendors that include Bullhorn Inc., ClearCompany Inc., Cornerstone OnDemand Inc., Greenhouse Software Inc., iCIMS Inc., International Business Machines Corp., JobDiva Inc., Oracle Corp., SwipeClock LLC, and Symphony Talent LLC. Also, the applicant tracking systems market in the US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.Read the full report: https://www.reportlinker.com/p03793938/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001